{"analyses":[{"ciLowerLimit":"13.0","ciNumSides":"TWO_SIDED","ciPctValue":"99","ciUpperLimit":"30.3","estimateComment":"Strata adjusted difference (Arm C - Concurrent Arm B) based on the CMH method of weighting. Stratified by PD-L1 (≥ 1% vs \\<1%/unevaluable/indeterminate), disease stage (IB/II vs IIIA), and sex (male vs female)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"% Difference","paramValue":"21.6"},{"ciLowerLimit":"3.49","ciNumSides":"TWO_SIDED","ciPctValue":"99","ciUpperLimit":"55.75","estimateComment":"Strata adjusted odds ratio (Arm C over Concurrent Arm B) the Mantel-Haenszel method. Stratified by PD-L1 (≥ 1% vs \\<1%/unevaluable/indeterminate), disease stage (IB/II vs IIIA), and sex (male vs female)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Odds Ratio (OR)","paramValue":"13.94","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"43"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"179"}],"units":"Participants"}],"description":"Pathologic complete response (pCR) rate is defined as the number of randomized participants with absence of residual tumor in lung and lymph nodes as evaluated by blinded independent pathological review (BIPR).","groups":[{"description":"Participants receive investigator-choice of platinum doublet chemotherapy regimens in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days).\n\nFollowing definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.","id":"OG000","title":"Arm B: Platinum Doublet Chemo"},{"description":"Participants receive nivolumab 360 mg IV + platinum doublet chemotherapy in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days).\n\nFollowing definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.","id":"OG001","title":"Arm C: Nivo 360 mg + Platinum Doublet Chemo"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All concurrently randomized participants in Arm C and Arm B","reportingStatus":"POSTED","timeFrame":"From randomization up to a median of 30 months after randomization.","title":"Pathologic Complete Response (pCR) Rate","type":"PRIMARY","unitOfMeasure":"Participants"}